{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T04:20:32Z","timestamp":1773030032880,"version":"3.50.1"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,8,17]],"date-time":"2021-08-17T00:00:00Z","timestamp":1629158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,8,17]],"date-time":"2021-08-17T00:00:00Z","timestamp":1629158400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Geriatr Med"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1007\/s41999-021-00553-w","type":"journal-article","created":{"date-parts":[[2021,8,17]],"date-time":"2021-08-17T09:02:42Z","timestamp":1629190962000},"page":"19-32","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Is there a link between the use of benzodiazepines and related drugs and dementia? A systematic review of reviews"],"prefix":"10.1007","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8745-5854","authenticated-orcid":false,"given":"Patr\u00edcia","family":"Ferreira","sequence":"first","affiliation":[]},{"given":"Ana Rita","family":"Ferreira","sequence":"additional","affiliation":[]},{"given":"Beatriz","family":"Barreto","sequence":"additional","affiliation":[]},{"given":"Lia","family":"Fernandes","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2021,8,17]]},"reference":[{"key":"553_CR1","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s40263-018-0535-3","volume":"32","author":"R Penninkilampi","year":"2018","unstructured":"Penninkilampi R, Eslick GD (2018) A systematic review and meta-analysis of the risk of dementia associated with benzodiazepine use, after controlling for protopathic bias. CNS Drugs 32:485\u2013497. https:\/\/doi.org\/10.1007\/s40263-018-0535-3","journal-title":"CNS Drugs"},{"key":"553_CR2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0127836","volume":"10","author":"G Zhong","year":"2015","unstructured":"Zhong G, Wang Y, Zhang Y, Zhao Y (2015) Association between benzodiazepine use and dementia: a meta-analysis. PLoS ONE 10:e0127836. https:\/\/doi.org\/10.1371\/journal.pone.0127836","journal-title":"PLoS ONE"},{"key":"553_CR3","unstructured":"Dementia: number of people affected to triple in next 30 years. In: Organization WH (2017) https:\/\/www.who.int\/news\/item\/07-12-2017-dementia-number-of-people-affected-to-triple-in-next-30-years. Accessed 29 Nov 2020"},{"key":"553_CR4","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/S0140-6736(20)30367-6","volume":"396","author":"G Livingston","year":"2020","unstructured":"Livingston G, Huntley J, Sommerlad A, Ames D, Ballard C, Banerjee S et al (2020) Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet 396:413\u2013446. https:\/\/doi.org\/10.1016\/S0140-6736(20)30367-6","journal-title":"Lancet"},{"key":"553_CR5","doi-asserted-by":"crossref","unstructured":"Bellou V, Belbasis L, Evangelou E (2020) Environmental and genetic risk factors for dementia. pp 165\u2013181","DOI":"10.1016\/B978-0-12-815854-8.00011-2"},{"key":"553_CR6","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.jalz.2016.07.152","volume":"13","author":"V Bellou","year":"2017","unstructured":"Bellou V, Belbasis L, Tzoulaki I, Middleton LT, Ioannidis JP, Evangelou E (2017) Systematic evaluation of the associations between environmental risk factors and dementia: an umbrella review of systematic reviews and meta-analyses. Alzheimer\u2019s Dementia 13:406\u2013418. https:\/\/doi.org\/10.1016\/j.jalz.2016.07.152","journal-title":"Alzheimer's Dementia"},{"key":"553_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2019.00344","author":"M Ettcheto","year":"2020","unstructured":"Ettcheto M, Olloquequi J, Sanchez-Lopez E, Busquets O, Cano A, Manzine PR et al (2020) Benzodiazepines and related drugs as a risk factor in Alzheimer\u2019s disease dementia. Front Aging Neurosci. https:\/\/doi.org\/10.3389\/fnagi.2019.00344","journal-title":"Front Aging Neurosci"},{"key":"553_CR8","doi-asserted-by":"publisher","first-page":"E6","DOI":"10.2146\/ajhp160381","volume":"75","author":"JD Picton","year":"2018","unstructured":"Picton JD, Marino AB, Nealy KL (2018) Benzodiazepine use and cognitive decline in the elderly. Am J Health Syst Pharm 75:E6\u2013E12. https:\/\/doi.org\/10.2146\/ajhp160381","journal-title":"Am J Health Syst Pharm"},{"key":"553_CR9","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.carage.2015.01.006","volume":"16","author":"C Cowles","year":"2015","unstructured":"Cowles C (2015) Benzodiazepine use increases with age, despite risks. Caring Ages 16:5. https:\/\/doi.org\/10.1016\/j.carage.2015.01.006","journal-title":"Caring Ages"},{"key":"553_CR10","doi-asserted-by":"publisher","first-page":"5","DOI":"10.2217\/nmt-2020-0056","volume":"11","author":"A Gupta","year":"2021","unstructured":"Gupta A, Bhattacharya G, Balaram K, Tampi D, Tampi RR (2021) Benzodiazepine use among older adults. Neurodegener Dis Manag 11:5\u20138. https:\/\/doi.org\/10.2217\/nmt-2020-0056","journal-title":"Neurodegener Dis Manag"},{"issue":"Suppl 1","key":"553_CR11","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1002\/pds.3825","volume":"25","author":"C Huerta","year":"2016","unstructured":"Huerta C, Abbing-Karahagopian V, Requena G, Oliva B, Alvarez Y, Gardarsdottir H et al (2016) Exposure to benzodiazepines (anxiolytics, hypnotics and related drugs) in seven European electronic healthcare databases: a cross-national descriptive study from the PROTECT-EU Project. Pharmacoepidemiol Drug Saf 25(Suppl 1):56\u201365. https:\/\/doi.org\/10.1002\/pds.3825","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"553_CR12","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1016\/j.mayocp.2016.07.024","volume":"91","author":"M Markota","year":"2016","unstructured":"Markota M, Rummans TA, Bostwick JM, Lapid MI (2016) Benzodiazepine use in older adults: dangers, management, and alternative therapies. Mayo Clin Proc 91:1632\u20131639. https:\/\/doi.org\/10.1016\/j.mayocp.2016.07.024","journal-title":"Mayo Clin Proc"},{"key":"553_CR13","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1001\/jamapsychiatry.2014.1763","volume":"72","author":"M Olfson","year":"2015","unstructured":"Olfson M, King M, Schoenbaum M (2015) Benzodiazepine use in the United States. JAMA Psychiat 72:136\u2013142. https:\/\/doi.org\/10.1001\/jamapsychiatry.2014.1763","journal-title":"JAMA Psychiat"},{"key":"553_CR14","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.drugalcdep.2019.02.033","volume":"200","author":"VR Votaw","year":"2019","unstructured":"Votaw VR, Geyer R, Rieselbach MM, McHugh RK (2019) The epidemiology of benzodiazepine misuse: a systematic review. Drug Alcohol Depend 200:95\u2013114. https:\/\/doi.org\/10.1016\/j.drugalcdep.2019.02.033","journal-title":"Drug Alcohol Depend"},{"key":"553_CR15","doi-asserted-by":"publisher","unstructured":"Health at a Glance 2019: OECD Indicators (2019) In: OECD. https:\/\/doi.org\/10.1787\/4dd50c09-en. Accessed 29 Nov 2020","DOI":"10.1787\/4dd50c09-en"},{"key":"553_CR16","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.maturitas.2017.04.002","volume":"101","author":"MJ D\u00edaz-Guti\u00e9rrez","year":"2017","unstructured":"D\u00edaz-Guti\u00e9rrez MJ, Mart\u00ednez-Cengotitabengoa M, de Adana ES, Cano AI, Mart\u00ednez-Cengotitabengoa MT, Besga A et al (2017) Relationship between the use of benzodiazepines and falls in older adults: a systematic review. Maturitas 101:17\u201322. https:\/\/doi.org\/10.1016\/j.maturitas.2017.04.002","journal-title":"Maturitas"},{"key":"553_CR17","first-page":"214","volume":"13","author":"CE Griffin 3rd","year":"2013","unstructured":"Griffin CE 3rd, Kaye AM, Bueno FR, Kaye AD (2013) Benzodiazepine pharmacology and central nervous system-mediated effects. Ochsner J 13:214\u2013223","journal-title":"Ochsner J"},{"key":"553_CR18","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.cger.2014.04.008","volume":"30","author":"A Kuerbis","year":"2014","unstructured":"Kuerbis A, Sacco P, Blazer DG, Moore AA (2014) Substance abuse among older adults. Clin Geriatr Med 30:629\u2013654. https:\/\/doi.org\/10.1016\/j.cger.2014.04.008","journal-title":"Clin Geriatr Med"},{"key":"553_CR19","doi-asserted-by":"publisher","first-page":"120","DOI":"10.9740\/mhc.2016.05.120","volume":"6","author":"A Schmitz","year":"2016","unstructured":"Schmitz A (2016) Benzodiazepine use, misuse, and abuse: a review. Ment Health Clin 6:120\u2013126. https:\/\/doi.org\/10.9740\/mhc.2016.05.120","journal-title":"Ment Health Clin"},{"key":"553_CR20","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1097\/HRP.0000000000000190","volume":"26","author":"LB Gerlach","year":"2018","unstructured":"Gerlach LB, Wiechers IR, Maust DT (2018) Prescription benzodiazepine use among older adults: a critical review. Harv Rev Psychiatry 26:264\u2013273. https:\/\/doi.org\/10.1097\/HRP.0000000000000190","journal-title":"Harv Rev Psychiatry"},{"key":"553_CR21","doi-asserted-by":"publisher","DOI":"10.1007\/s11920-016-0727-9","author":"G Airagnes","year":"2016","unstructured":"Airagnes G, Pelissolo A, Lavallee M, Flament M, Limosin F (2016) Benzodiazepine misuse in the elderly: risk factors, consequences, and management. Curr Psychiatry Rep. https:\/\/doi.org\/10.1007\/s11920-016-0727-9","journal-title":"Curr Psychiatry Rep"},{"issue":"63","key":"553_CR22","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1111\/jgs.13702","volume":"2015","author":"American Geriatrics Society","year":"2015","unstructured":"American Geriatrics Society (2015) Updated beers criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc 2015(63):2227\u20132246. https:\/\/doi.org\/10.1111\/jgs.13702","journal-title":"J Am Geriatr Soc"},{"key":"553_CR23","doi-asserted-by":"publisher","first-page":"349","DOI":"10.2165\/00002512-199303040-00005","volume":"3","author":"JD Bowen","year":"1993","unstructured":"Bowen JD, Larson EB (1993) Drug-induced cognitive impairment. Defining the problem and finding solutions. Drugs Aging 3:349\u2013357. https:\/\/doi.org\/10.2165\/00002512-199303040-00005","journal-title":"Drugs Aging"},{"issue":"67","key":"553_CR24","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1111\/jgs.15767","volume":"2019","author":"American Geriatrics Society","year":"2019","unstructured":"American Geriatrics Society (2019) Updated AGS beers criteria\u00ae for potentially inappropriate medication use in older adults. J Am Geriatr Soc 2019(67):674\u2013694. https:\/\/doi.org\/10.1111\/jgs.15767","journal-title":"J Am Geriatr Soc"},{"key":"553_CR25","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1159\/000289072","volume":"65","author":"F Lechin","year":"1996","unstructured":"Lechin F, vander Dijs B, Benaim M (1996) Benzodiazepines: tolerability in elderly patients. Psychother Psychosom 65:171\u2013182. https:\/\/doi.org\/10.1159\/000289072","journal-title":"Psychother Psychosom"},{"key":"553_CR26","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1002\/ana.21509","volume":"64","author":"H Amieva","year":"2008","unstructured":"Amieva H, Le Goff M, Millet X, Orgogozo JM, P\u00e9r\u00e8s K, Barberger-Gateau P et al (2008) Prodromal Alzheimer\u2019s disease: successive emergence of the clinical symptoms. Ann Neurol 64:492\u2013498. https:\/\/doi.org\/10.1002\/ana.21509","journal-title":"Ann Neurol"},{"key":"553_CR27","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s40268-017-0207-7","volume":"17","author":"J Brandt","year":"2017","unstructured":"Brandt J, Leong C (2017) Benzodiazepines and Z-drugs: an updated review of major adverse outcomes reported on in epidemiologic research. Drugs R D 17:493\u2013507. https:\/\/doi.org\/10.1007\/s40268-017-0207-7","journal-title":"Drugs R D"},{"key":"553_CR28","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1177\/2045125317753340","volume":"8","author":"D Fluyau","year":"2018","unstructured":"Fluyau D, Revadigar N, Manobianco BE (2018) Challenges of the pharmacological management of benzodiazepine withdrawal, dependence, and discontinuation. Ther Adv Psychopharmacol 8:147\u2013168. https:\/\/doi.org\/10.1177\/2045125317753340","journal-title":"Ther Adv Psychopharmacol"},{"key":"553_CR29","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.2147\/NDT.S83130","volume":"11","author":"B Dell'Osso","year":"2015","unstructured":"Dell\u2019Osso B, Albert U, Atti AR, Carmassi C, Carr\u00e0 G, Cosci F et al (2015) Bridging the gap between education and appropriate use of benzodiazepines in psychiatric clinical practice. Neuropsychiatr Dis Treat 11:1885\u20131909. https:\/\/doi.org\/10.2147\/NDT.S83130","journal-title":"Neuropsychiatr Dis Treat"},{"key":"553_CR30","doi-asserted-by":"publisher","first-page":"101","DOI":"10.2165\/00002018-199921020-00004","volume":"21","author":"SL Gray","year":"1999","unstructured":"Gray SL, Lai KV, Larson EB (1999) Drug-induced cognition disorders in the elderly\u2014incidence, prevention and management. Drug Saf 21:101\u2013122. https:\/\/doi.org\/10.2165\/00002018-199921020-00004","journal-title":"Drug Saf"},{"key":"553_CR31","first-page":"224","volume":"88","author":"B Johnson","year":"2013","unstructured":"Johnson B, Streltzer J (2013) Risks associated with long-term benzodiazepine use. Am Fam Physician 88:224\u2013226","journal-title":"Am Fam Physician"},{"key":"553_CR32","doi-asserted-by":"publisher","first-page":"16551","DOI":"10.1038\/s41598-020-73680-2","volume":"10","author":"M Liu","year":"2020","unstructured":"Liu M, Dexheimer T, Sui D, Hovde S, Deng X, Kwok R et al (2020) Hyperphosphorylated tau aggregation and cytotoxicity modulators screen identified prescription drugs linked to Alzheimer\u2019s disease and cognitive functions. Sci Rep 10:16551. https:\/\/doi.org\/10.1038\/s41598-020-73680-2","journal-title":"Sci Rep"},{"key":"553_CR33","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.neurobiolaging.2018.10.027","volume":"75","author":"RA Whittington","year":"2019","unstructured":"Whittington RA, Vir\u00e1g L, Gratuze M, Lewkowitz-Shpuntoff H, Cheheltanan M, Petry F et al (2019) Administration of the benzodiazepine midazolam increases tau phosphorylation in the mouse brain. Neurobiol Aging 75:11\u201324. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2018.10.027","journal-title":"Neurobiol Aging"},{"key":"553_CR34","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3988\/jcn.2019.15.1.9","volume":"15","author":"Q He","year":"2019","unstructured":"He Q, Chen X, Wu T, Li L, Fei X (2019) Risk of dementia in long-term benzodiazepine users: evidence from a meta-analysis of observational studies. J Clin Neurol 15:9\u201319. https:\/\/doi.org\/10.3988\/jcn.2019.15.1.9","journal-title":"J Clin Neurol"},{"key":"553_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40263-015-0305-4","volume":"30","author":"A Pariente","year":"2016","unstructured":"Pariente A, de Gage SB, Moore N, B\u00e9gaud B (2016) The benzodiazepine-dementia disorders link: current state of knowledge. CNS Drugs 30:1\u20137. https:\/\/doi.org\/10.1007\/s40263-015-0305-4","journal-title":"CNS Drugs"},{"key":"553_CR36","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1016\/j.jagp.2016.04.013","volume":"24","author":"JK Chung","year":"2016","unstructured":"Chung JK, Nakajima S, Shinagawa S, Plitman E, Chakravarty MM, Iwata Y et al (2016) Benzodiazepine use attenuates cortical \u03b2-amyloid and is not associated with progressive cognitive decline in nondemented elderly adults: a pilot study using F(18)-florbetapir positron emission tomography. Am J Geriatr Psychiatry 24:1028\u20131039. https:\/\/doi.org\/10.1016\/j.jagp.2016.04.013","journal-title":"Am J Geriatr Psychiatry"},{"key":"553_CR37","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b2700","volume":"339","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J, Mulrow C, G\u00f8tzsche PC, Ioannidis JP et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 339:b2700. https:\/\/doi.org\/10.1136\/bmj.b2700","journal-title":"BMJ"},{"key":"553_CR38","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/1471-2288-11-15","volume":"11","author":"V Smith","year":"2011","unstructured":"Smith V, Devane D, Begley CM, Clarke M (2011) Methodology in conducting a systematic review of systematic reviews of healthcare interventions. BMC Med Res Methodol 11:15. https:\/\/doi.org\/10.1186\/1471-2288-11-15","journal-title":"BMC Med Res Methodol"},{"key":"553_CR39","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j4008","volume":"358","author":"BJ Shea","year":"2017","unstructured":"Shea BJ, Reeves BC, Wells G, Thuku M, Hamel C, Moran J et al (2017) AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ 358:j4008. https:\/\/doi.org\/10.1136\/bmj.j4008","journal-title":"BMJ"},{"key":"553_CR40","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s41073-019-0064-8","volume":"4","author":"C Baethge","year":"2019","unstructured":"Baethge C, Goldbeck-Wood S, Mertens S (2019) SANRA-a scale for the quality assessment of narrative review articles. Res Integr Peer Rev 4:5. https:\/\/doi.org\/10.1186\/s41073-019-0064-8","journal-title":"Res Integr Peer Rev"},{"key":"553_CR41","unstructured":"Benzodiazepines: dementia in the elderly? Prescrire Int. 2017 26:16\u201317"},{"key":"553_CR42","doi-asserted-by":"publisher","first-page":"3413","DOI":"10.1111\/bph.14607","volume":"176","author":"R Barus","year":"2019","unstructured":"Barus R, B\u00e9n\u00e9 J, Deguil J, Gautier S, Bordet R (2019) Drug interactions with dementia-related pathophysiological pathways worsen or prevent dementia. Br J Pharmacol 176:3413\u20133434. https:\/\/doi.org\/10.1111\/bph.14607","journal-title":"Br J Pharmacol"},{"key":"553_CR43","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1517\/14740338.2015.1014796","volume":"14","author":"SB de Gage","year":"2015","unstructured":"de Gage SB, Pariente A, B\u00e9gaud B (2015) Is there really a link between benzodiazepine use and the risk of dementia? Expert Opin Drug Saf 14:733\u2013747. https:\/\/doi.org\/10.1517\/14740338.2015.1014796","journal-title":"Expert Opin Drug Saf"},{"key":"553_CR44","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1159\/000454881","volume":"47","author":"MM Islam","year":"2016","unstructured":"Islam MM, Iqbal U, Walther B, Atique S, Dubey NK, Nguyen PA et al (2016) Benzodiazepine use and risk of dementia in the elderly population: a systematic review and meta-analysis. Neuroepidemiology 47:181\u2013191. https:\/\/doi.org\/10.1159\/000454881","journal-title":"Neuroepidemiology"},{"key":"553_CR45","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.therap.2018.09.071","volume":"74","author":"M Lapeyre-Mestre","year":"2019","unstructured":"Lapeyre-Mestre M (2019) Benzodiazepines, cognitive decline and dementia: a review of causality criteria from published observational studies. Therapie 74:407\u2013419. https:\/\/doi.org\/10.1016\/j.therap.2018.09.071","journal-title":"Therapie"},{"key":"553_CR46","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1002\/phar.2170","volume":"38","author":"RC Lucchetta","year":"2018","unstructured":"Lucchetta RC, da Mata BPM, Mastroianni PC (2018) Association between development of dementia and use of benzodiazepines: a systematic review and meta-analysis. Pharmacotherapy 38:1010\u20131020. https:\/\/doi.org\/10.1002\/phar.2170","journal-title":"Pharmacotherapy"},{"key":"553_CR47","doi-asserted-by":"publisher","first-page":"209","DOI":"10.2217\/fnl-2017-0040","volume":"13","author":"RR Tampi","year":"2018","unstructured":"Tampi RR, Tampi DJ, Young JJ, Banerjee A (2018) Benzodiazepine use and the risk for dementia. Future Neurol 13:209\u2013217. https:\/\/doi.org\/10.2217\/fnl-2017-0040","journal-title":"Future Neurol"},{"key":"553_CR48","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1017\/s0033291704003897","volume":"35","author":"H Verdoux","year":"2005","unstructured":"Verdoux H, Lagnaoui R, Begaud B (2005) Is benzodiazepine use a risk factor for cognitive decline and dementia? A literature review of epidemiological studies. Psychol Med 35:307\u2013315. https:\/\/doi.org\/10.1017\/s0033291704003897","journal-title":"Psychol Med"},{"key":"553_CR49","doi-asserted-by":"publisher","first-page":"149","DOI":"10.32385\/rpmgf.v34i3.12447","volume":"34","author":"SG Domingues","year":"2018","unstructured":"Domingues SG, Gomes VRP (2018) Benzodiazepinas e risco de dem\u00eancia: qual a evid\u00eancia? Revista Portuguesa de Medicina Geral e Familiar 34:149\u2013155","journal-title":"Revista Portuguesa de Medicina Geral e Familiar"},{"key":"553_CR50","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s00228-004-0808-2","volume":"60","author":"R Lagnaoui","year":"2004","unstructured":"Lagnaoui R, Depont F, Fourrier A, Abouelfath A, B\u00e9gaud B, Verdoux H et al (2004) Patterns and correlates of benzodiazepine use in the French general population. Eur J Clin Pharmacol 60:523\u2013529. https:\/\/doi.org\/10.1007\/s00228-004-0808-2","journal-title":"Eur J Clin Pharmacol"},{"key":"553_CR51","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1097\/YIC.0b013e328105e0f2","volume":"22","author":"S Petitjean","year":"2007","unstructured":"Petitjean S, Ladewig D, Meier CR, Amrein R, Wiesbeck GA (2007) Benzodiazepine prescribing to the Swiss adult population: results from a national survey of community pharmacies. Int Clin Psychopharmacol 22:292\u2013298. https:\/\/doi.org\/10.1097\/YIC.0b013e328105e0f2","journal-title":"Int Clin Psychopharmacol"},{"key":"553_CR52","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s12874-016-0183-6","volume":"16","author":"U Wegewitz","year":"2016","unstructured":"Wegewitz U, Weikert B, Fishta A, Jacobs A, Pieper D (2016) Resuming the discussion of AMSTAR: What can (should) be made better? BMC Med Res Methodol 16:111. https:\/\/doi.org\/10.1186\/s12874-016-0183-6","journal-title":"BMC Med Res Methodol"},{"key":"553_CR53","volume-title":"Shorter oxford textbook of psychiatry","author":"P Harrison","year":"2018","unstructured":"Harrison P, Cowen P, Burns T, Fazel M (2018) Shorter oxford textbook of psychiatry, 7th edn. University Press, Oxford","edition":"7"},{"key":"553_CR54","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1177\/0269881112444324","volume":"26","author":"A Lingford-Hughes","year":"2012","unstructured":"Lingford-Hughes A, Welch S, Peters L, Nutt D (2012) BAP updated guidelines: evidence-based guidelines for the pharmacological management of substance abuse, harmful use, addiction and comorbidity: recommendations from BAP. J Psychopharmacol 26:899\u2013952. https:\/\/doi.org\/10.1177\/0269881112444324","journal-title":"J Psychopharmacol"}],"container-title":["European Geriatric Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41999-021-00553-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s41999-021-00553-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41999-021-00553-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T21:17:36Z","timestamp":1645478256000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s41999-021-00553-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,17]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["553"],"URL":"https:\/\/doi.org\/10.1007\/s41999-021-00553-w","relation":{},"ISSN":["1878-7657"],"issn-type":[{"value":"1878-7657","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,17]]},"assertion":[{"value":"1 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}